Ignite Creation Date:
2024-05-06 @ 10:25 AM
Last Modification Date:
2024-10-26 @ 12:29 PM
Study NCT ID:
NCT03250377
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-05-31
First Post:
2017-07-31
Brief Title:
A Study to Test the Safety Efficacy of Brivaracetam BRV Used as Adjunctive Treatment in Subjects 16 Years of Age With Partial Seizures With or Without Secondary Generalization
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
An Open-Label Multicenter Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects 16 Years of Age With Partial Seizures With or Without Secondary Generalization
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam BRV in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None